Processa Pharmaceuticals reports positive Phase 2 update for NGC-cap in cancer treatment
Processa Pharmaceuticals (NASDAQ:PCSA) provided a Phase 2 clinical update for its combination therapy, NGC-Cap (PCS6422 + capecitabine), on December 17, 2025.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Processa Pharmaceuticals (NASDAQ:PCSA) provided a Phase 2 clinical update for its combination therapy, NGC-Cap (PCS6422 + capecitabine), on December 17, 2025.
Vistagen (NASDAQ:VTGN) announced disappointing results from its PALISADE-3 Phase 3 clinical trial of intranasal fasedienol, a treatment for social anxiety disorder.
The study failed to meet its primary endpoint, which was based on the change from baseline in the Subjective Units of Distress Scale (SUDS).
SCHMID Group (NASDAQ:SHMD) reported its unaudited H1 2025 financial results, revealing a significant decline in revenue to €16.9 million, compared to €29.7 million in the same period a year earlier.
Toro Co. (NYSE:TTC) reported a profit of $73 million for its fiscal fourth quarter, or 74 cents per share, beating Wall Street expectations.
Traws Pharma (NASDAQ:TRAW) reported promising interim results from its Phase 2 trial of ratutrelvir, a ritonavir-free Mpro inhibitor, in the treatment of COVID-19.
The oral treatment, administered at a 600 mg once-daily dose for 10 days, was compared against PAXLOVID™ in a randomized, open-label study involving 37 patients—25 receiving ratutrelvir and 12 receiving PAXLOVID™.
Dyadic (NASDAQ:DYAI) has expanded its strategic collaboration with Fermbox Bio to enhance the manufacturing, commercialization, and dual-sourcing of animal-free proteins and enzymes developed by Dyadic.
NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.
Cytokinetics (NASDAQ:CYTK) announced that its drug MYQORZO (aficamten) has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adults with NYHA class II-III obstructive hypertrophic cardiomyopathy.
Spire Global (NYSE:SPIR), a leading satellite data provider, reported a revenue decline for the third quarter of 2025, posting $12.7 million in sales, a drop from the same period last year.
Steel Dynamics (NASDAQ:STLD) has provided its earnings guidance for the fourth quarter of fiscal year 2025, forecasting a range of $1.65 to $1.69 per diluted share.
This represents a notable decline from the $2.74 per share earnings reported in the third quarter of 2025, but an increase over the $1.36 per share reported in Q4 2024.
Coursera (NYSE:COUR) and Udemy (NASDAQ:UDMY) announced today that they have entered into a definitive merger agreement to combine in an all-stock transaction valued at approximately $2.5 billion.
Wiley (NYSE:WLY), a global leader in scientific content and research intelligence, has announced a quarterly cash dividend of $0.355 per share, effective January 15, 2026.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade